Purpose: To evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or hemorrhage. Methods: A prospective, single practice, open label trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV in 13 eyes of 13 patients who completed the 1-year study. The primary outcome measure was stabilization of vision (loss of <15 ETDRS letters). Secondary outcome measures included incidence of ocular and systemic adverse events, changes in subretinal hemorrhage, central foveal thickness, and polypoidal complexes on indocyanine green angiography at 1 year. Results: No patient lost ≥15 letters in visual acuity at 1 year. Three patients (23%) gained ≥15 letters at 12 months. Subretinal hemorrhage resolved in 9/9 eyes (100%). Macular edema improved in 5/5 eyes (100%). Subretinal fluid completely resolved in 4/9 eyes (44%), decreased in 2/9 eyes (22%), and increased in 3/9 eyes (33%). Polypoidal complexes decreased in 5/13 eyes (38%). Conclusion: Continuous monthly intravitreal ranibizumab decreases leakage and hemorrhage in eyes with exudative and hemorrhagic complications of PCV. Branching vascular networks persisted, and polypoidal complexes decreased in only 5/13 (38%) eyes with continuous antiangiogenic therapy at 1 year.

Keywords:
Polypoidal choroidal vasculopathy, Hemorrhage, Exudation
1.
Yannuzzi LA, Sorensen J, Spaide RF, Lipson B: Idiopathic polypoidal choroidal vasculopathy. Retina 1990;10:1-8.
2.
Yannuzzi LA, Ciardella A, Spaide RF, et al: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478-485.
3.
Laude A, Cackett PD, Vithana E, et al: Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010;29:19-29.
4.
Spaide RF, Yannuzzi LA, Slakter JS, et al: Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100-110.
5.
Cohen S, Dubois L, Quentel G, Gaudric A: Editorial: is indocyanine green angiography still relevant? Retina 2011;31:209-221.
6.
Kokame GT: Polypoidal choroidal vasculopathy - an important diagnosis to make with therapeutic implications. Retina 2012;32:1446-1448.
7.
Uyama M, Wada M, Nagai Y, et al: Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639-648.
8.
Quaranta M, Mauget-Faysse M, Coscas G: Exudative idiopathic polypoidal choroidal vasculopathy with photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134:277-280.
9.
Chan WM, Lam DS, Lai TY, et al: Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology 2004;111:1576-1584.
10.
Gomi F, Ohji M, Sayanagi K, et al: One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141-146.
11.
Honda S, Kurimoto Y, Kagotania Y, et al: Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30 month multicenter study in Hyogo, Japan. Jpn J Ophthalmol 2009;53:593-597.
12.
Lee WK, Kim KS, Kim WJ, et al: Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of grape clusters. Am J Ophthalmol 2012;154:355-365.e1.
13.
Gomi F, Sawa M, Sakaguchi M, et al: Effect of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-73.
14.
Lee SY, Kim JG, Joe SG, et al: The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 2008;22:92-99.
15.
Cheng CK, Peng CH, Chang CK, et al: One-year outcomes of intravitreal bevacizumab (Avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011;31:846-856.
16.
Koh A, Lee WK, Chen LJ, et al: EVEREST study: efficacy and safety of verteporfin photodynamic therapy with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32:1453-1464.
17.
Kokame GT, Yeung L, Lai JC: Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6 month results. Br J Ophthalmol 2010;94:297-301.
18.
Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
19.
Brown DM, Michels M, Kaiser PK, et al: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
20.
Yamashiro K, Tomita K, Tsujikawa A, et al: Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154:125-136.
21.
Stangos AN, Gandhi JS, Nair-Sahni J, et al: Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150:666-673.
22.
Cho M, Barbazetto IA, Freund KB: Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148:70-78.
23.
Gomi F, Tano Y: Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 2008;19:208-212.
24.
Isola V, Pece A, Parodi MB: Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol 2006;142:680-683.
25.
Jalil A, Mercieca K, Chaudhry NL, Stanga PE: Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: an OCT and FFA study. Eur J Ophthalmol 2009;19:490-493.
26.
Sagong M, Lim S, Chang W: Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2012;153:873-882.
27.
Tomita K, Tsujikawa A, Yamashiro K, et al: Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012;153:68-80.
28.
Ciardella AP, Donsoff IM, Huang SJ, et al: Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49:25-37.
29.
Freund KB, Zweifel SA, Engelbert M: Editorial: do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30:1333-1349.
30.
Gass JD: Stereoscopic Atlas of Macular Diseases, ed 4. St. Louis, Mosby, 1997, pp 26-30.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.